Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $150.46M.
ENTERPRISE VALUE (EV)
$150.46M
Niagen Bioscience Inc
Market Cap
$214.24M
Enterprise Value (EV)
$150.46M
Market Cap
$215.07M
Enterprise Value (EV)
$207.30M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.24M | $150.46M |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | $159.21M |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | $207.30M |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | $208.23M |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | $174.93M |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | $159.67M |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | $202.65M |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | $189.92M |
Market Cap
$214.24M
Total Debt
$1.00M
Cash
$64.79M
Enterprise Value
$150.46M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
